This invention includes novel compounds that have neuropharmacological activity with the dopamine receptor and the method of using them to treat central nervous system disorders.
Background & Unmet Need:
The dopamine transporter (DAT) plays an important role in processes of the central nervous system. In cocaine addiction, binding of cocaine to the DAT and consequent blockage of dopamine uptake is related to the reinforcing properties of the drug. Also associated with the transport function is concentration of neurotoxic chemicals in dopaminergic neurons, which is implicated in Parkinson’s disease. Potent, yet selective ligands for the DAT have potential for monitoring of primary targets of cocaine in the brain, for the characterization of cocaine binding sites, for pharmacotherapeutic agents for the treatment of cocaine addiction, and for monitoring of Parkinson’s disease.
Technology Description:
Novel compounds have been developed in a few different molecular templates. These compounds have exhibited neuropharmacological activity with respect to their interaction with the dopamine transporter, the serotonin transporter (SERT) and the norepinepherine transporter (NET). These compounds have utility in treating central nervous system disorders, including cocaine addiction, depression, and Parkinson’s disease.
Commercial Applications:
· Medications for neurodegenerative diseases
· Treatment for addiction
Stage of Development:
Preclinical
Competitive Advantages:
- Low nanomolar activity with respect to DAT
- High differential binding activity compared to SERT and NET
Intellectual Property Status:
U.S. patent #6,995,268
Related Publications or Citations of Work:
None